2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      C5a impairs phagosomal maturation in the neutrophil through phosphoproteomic remodeling

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Critical illness is accompanied by the release of large amounts of the anaphylotoxin, C5a. C5a suppresses antimicrobial functions of neutrophils which is associated with adverse outcomes. The signaling pathways that mediate C5a-induced neutrophil dysfunction are incompletely understood. Healthy donor neutrophils exposed to purified C5a demonstrated a prolonged defect (7 hours) in phagocytosis of Staphylococcus aureus. Phosphoproteomic profiling of 2712 phosphoproteins identified persistent C5a signaling and selective impairment of phagosomal protein phosphorylation on exposure to S. aureus. Notable proteins included early endosomal marker ZFYVE16 and V-ATPase proton channel component ATPV1G1. An assay of phagosomal acidification demonstrated C5a-induced impairment of phagosomal acidification, which was recapitulated in neutrophils from critically ill patients. Examination of the C5a-impaired protein phosphorylation indicated a role for the PI3K VPS34 in phagosomal maturation. Inhibition of VPS34 impaired neutrophil phagosomal acidification and killing of S. aureus. This study provides a phosphoproteomic assessment of human neutrophil signaling in response to S. aureus and its disruption by C5a, identifying a defect in phagosomal maturation and mechanisms of immune failure in critical illness.

          Abstract

          Abstract

          C5a disrupts the neutrophil phosphoproteomic response to bacteria, impairing phagosomal maturation and bacterial killing.

          Related collections

          Most cited references58

          • Record: found
          • Abstract: found
          • Article: not found

          A novel mechanism of rapid nuclear neutrophil extracellular trap formation in response to Staphylococcus aureus.

          Neutrophil extracellular traps (NETs) are webs of DNA covered with antimicrobial molecules that constitute a newly described killing mechanism in innate immune defense. Previous publications reported that NETs take up to 3-4 h to form via an oxidant-dependent event that requires lytic death of neutrophils. In this study, we describe neutrophils responding uniquely to Staphylococcus aureus via a novel process of NET formation that did not require neutrophil lysis or even breach of the plasma membrane. The multilobular nucleus rapidly became rounded and condensed. During this process, we observed the separation of the inner and outer nuclear membranes and budding of vesicles, and the separated membranes and vesicles were filled with nuclear DNA. The vesicles were extruded intact into the extracellular space where they ruptured, and the chromatin was released. This entire process occurred via a unique, very rapid (5-60 min), oxidant-independent mechanism. Mitochondrial DNA constituted very little if any of these NETs. They did have a limited amount of proteolytic activity and were able to kill S. aureus. With time, the nuclear envelope ruptured, and DNA filled the cytoplasm presumably for later lytic NET production, but this was distinct from the vesicular release mechanism. Panton-Valentine leukocidin, autolysin, and a lipase were identified in supernatants with NET-inducing activity, but Panton-Valentine leukocidin was the dominant NET inducer. We describe a new mechanism of NET release that is very rapid and contributes to trapping and killing of S. aureus.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Endocytosis and signalling: intertwining molecular networks.

            Cell signalling and endocytic membrane trafficking have traditionally been viewed as distinct processes. Although our present understanding is incomplete and there are still great controversies, it is now recognized that these processes are intimately and bidirectionally linked in animal cells. Indeed, many recent examples illustrate how endocytosis regulates receptor signalling (including signalling from receptor tyrosine kinases and G protein-coupled receptors) and, conversely, how signalling regulates the endocytic pathway. The mechanistic and functional principles that underlie the relationship between signalling and endocytosis in cell biology are becoming increasingly evident across many systems.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Advances in the understanding and treatment of sepsis-induced immunosuppression

              Sepsis is defined as a life-threatening organ dysfunction that is caused by a dysregulated host response to infection. Sepsis can induce acute kidney injury and multiple organ failures and represents the most common cause of death in the intensive care unit. Sepsis initiates a complex immune response that varies over time, with the concomitant occurrence of both pro-inflammatory and anti-inflammatory mechanisms. As a result, most patients with sepsis rapidly display signs of profound immunosuppression, which is associated with deleterious consequences. Scientific advances have highlighted the role of metabolic failure, epigenetic reprogramming, myeloid-derived suppressor cells, immature suppressive neutrophils and immune alterations in primary lymphoid organs (the thymus and bone marrow) in sepsis. An improved understanding of the mechanisms underlying this immunosuppression as well as of the similarities between sepsis-induced immunosuppression and immune defects in cancer or immunosenescence has led to novel therapeutic strategies aimed at stimulating immune function in patients with sepsis. Trials assessing the therapeutic benefit of IL-7, granulocyte-macrophage colony-stimulating factor (GM-CSF) and antibodies against programmed cell death protein 1 (PD1) and programmed cell death 1 ligand 1 (PDL1) for the treatment of sepsis are in progress. The reappraisal of sepsis pathophysiology has also resulted in a novel approach to the design of clinical trials evaluating sepsis treatments, based on an evaluation of the immune status and biomarker-based stratification of patients.
                Bookmark

                Author and article information

                Contributors
                Journal
                JCI Insight
                JCI Insight
                JCI Insight
                JCI Insight
                American Society for Clinical Investigation
                2379-3708
                6 August 2020
                6 August 2020
                6 August 2020
                : 5
                : 15
                : e137029
                Affiliations
                [1 ]Department of Medicine, University of Cambridge, Addenbrooke’s Hospital, Hills Road, Cambridge, United Kingdom.
                [2 ]Faculty of Medical Sciences, Newcastle University, Framlington Place, Newcastle upon Tyne, United Kingdom.
                [3 ]Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, United Kingdom.
                [4 ]Newcastle upon Tyne Hospitals NHS Foundation Trust, Queen Victoria Road, Newcastle upon Tyne, United Kingdom.
                [5 ]National Heart and Lung Institute, Imperial College, London, United Kingdom.
                [6 ]Division of Immunology, Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge, United Kingdom.
                Author notes
                Address correspondence to: Andrea Conway Morris, Division of Anaesthesia, Department of Medicine, Level 4, Addenbrooke’s Hospital, Hills Road, Cambridge United Kingdom, CB2 0QQ. Phone: 44.1223.217889; Email: ac926@ 123456cam.ac.uk .
                Author information
                http://orcid.org/0000-0001-7819-0447
                http://orcid.org/0000-0002-4011-7452
                http://orcid.org/0000-0002-4650-8745
                http://orcid.org/0000-0003-4731-7294
                http://orcid.org/0000-0002-3228-9692
                http://orcid.org/0000-0002-7269-2873
                http://orcid.org/0000-0002-9432-4051
                http://orcid.org/0000-0002-3211-3216
                Article
                137029
                10.1172/jci.insight.137029
                7455072
                32634128
                c2639fc9-5656-4537-b6fe-5d65e74a1856
                © 2020 Wood et al.

                This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 2 March 2020
                : 24 June 2020
                Funding
                Funded by: Wellcome Trust, https://doi.org/10.13039/100004440;
                Award ID: (WT 2055214/Z/16/Z)
                Funded by: Gates Cambridge Trust, https://doi.org/10.13039/501100005370;
                Award ID: Grant to Alex Wood
                Funded by: European Society of Intensive Care Medicine
                Award ID: Young Investigator Award (ACM)
                Funded by: Academy of Medical Sciences, https://doi.org/10.13039/501100000691;
                Award ID: AMS-SGCL13-Conway-Morris
                Categories
                Research Article

                immunology,infectious disease,bacterial infections,complement,neutrophils

                Comments

                Comment on this article